Study #2024-0371
A Phase Ib study of Rezatapopt in combination with Azacitidine in patients with Relapsed/Refractory TP53 Y220C mutant myeloid malignancies (Acute Myeloid Leukemia or Myelodysplastic syndrome)
MD Anderson Study Status
Enrolling
Treatment Agent
Azacitidine, Rezatapopt
Description
A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.